ArriVent BioPharma, Inc.
AVBP
Positions held
Your positionsAVBP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $823.93M | Enterprise value | $451.16M | Trailing P/E | — | Forward P/E | -4.28 |
| PEG | — | Price / book | 2.20 | Beta | 1.35 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -53.3% | ROA | -33.1% | Debt / equity | 0.00 |
| Current ratio | 14.16 | Free cash flow | -$89.48M | Analyst recommendation | strong_buy | Mean target | $20.56 |
| 52w high | $35.83 | 52w low | $11.36 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$49.9M | -$43.3M | -$35.5M | -$35.0M | -$31.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$52.7M | -$46.1M | -$38.8M | -$38.3M | -$33.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$166M | -$80.5M | -$69.3M | -$36.9M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$178M | -$94.3M | -$74.6M | -$36.9M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
2026-10-07 · ArriVent’s stock plummets on Phase III NSCLC trial failure
2026-10-06 · Top Midday Decliners
2026-10-06 · ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
2026-10-06 · AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’
2026-10-06 · ArriVent collapses on disappointing lung cancer data
2026-10-06 · Why This Biotech Stock Is Having Its Worst Day Ever
2026-10-06 · ArriVent stock tumbles 60% after trial misses primary endpoint
2026-10-06 · ArriVent Says Cancer Drug Candidate Firmonertinib Misses Primary Endpoint in Phase 3 Trial; Shares Fall Pre-Bell
2026-08-12 · ArriVent BioPharma Reports Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patterns